RT Journal Article
SR Electronic
T1 TESTING, TRACING AND SOCIAL DISTANCING: ASSESSING OPTIONS FOR THE CONTROL OF COVID_19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.23.20077503
DO 10.1101/2020.04.23.20077503
A1 Humphrey, Lia
A1 Thommes, Edward W.
A1 Fields, Roie
A1 Coudeville, Laurent
A1 Hakim, Naseem
A1 Chit, Ayman
A1 Cojocaru, Monica G.
YR 2020
UL http://medrxiv.org/content/early/2020/07/26/2020.04.23.20077503.abstract
AB In this work we present an analysis of non-pharmaceutical interventions implemented around the world in the fight against COVID-19: Social distancing, shelter-in-place, mask wearing, etc measures to protect the susceptible, together with, in various degrees, testing & contact-tracing to identify, isolate and treat the infected. The majority of countries have relied on the former, while ramping up their testing and tracing capabilities. We consider the examples of South Korea, Italy, Canada and the United States. By fitting a disease transmission model to daily case report data, we show that in each of the four countries their combination of social-distancing and testing/tracing to date have had a significant impact on the evolution of their pandemic curves. In this work we estimate the average isolation rates of infected individuals needing to occur in each country as a result of large-scale testing and contact tracing as a mean of lifting social distancing measures, without a resurgence of COVID-19. We find that an average isolation rate of an infected individual every 4.5 days (South Korea), 5.7 days (Canada) and to 6 days (Italy) would be sufficient. We also find that a rate of under 3.5 days will help in the United States, although it would not completely mitigate the second wave the country is currently under.Competing Interest StatementEdward W. Thommes and Ayman Chit are employees of Sanofi Pasteur. Monica G. Cojocaru has received national research grants (NSERC CANADA) in the past, in which Sanofi Pasteur was a matching partner, however none of the work here was supported by those grants.Funding StatementNo third party payments have been received for this work. M. G. Cojocaru, L. Humphrey and R. Fields acknowledge support from the National Science and Engineering Research Council of Canada, Discovery Grant 400684 (PI: Cojocaru).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is from publicly available sources.